Increased oxacillin activity associated with glycopeptides in coagulase-negative staphylococci

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 17, Issue 3, 1998, Pages 143-150

  Domaracki, B E ^a   Evans, A ^a   Preston, K E ^a   Fraimow, H ^b   Venezia, R A ^a  

^a ALBANY MEDICAL CENTER   (United States)

^b GRADUATE HOSPITAL   (United States)

Author keywords

Coagulose negative staphylococci; Methicillin resistance; Staphylococcus; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE; GLYCOPEPTIDE; OXACILLIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; NONHUMAN; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS;

EID: 0031776259     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01691109     Document Type: Article

References (32)

1. Edmond MB, Wenzel RP, Pasculle AW: Vancomycin-resislant Staphylococcus aureus: perspectives on measures needed for control. Annals of Internal Medicine (1996) 124:329-334.
2. Georgopapadakou NH: Penicillin-binding proteins and bacterial resistance to β-lactams. Antimicrobial Agents and Chemotherapy (1993) 37:2045-2053.
3. Johnson AP, Uttley AHC, Woodford N, George RC: Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clinical Microbiology Reviews (1990) 3:280-291.
4. Aubert G, Passot S, Lucht F, Dorche G: Selection of vancomycin-and teicoplanin-resistant Staphylococcus haemolyticus during teicoplanin treatment of Staphylococcus epidermidis infection. Journal of Antimicrobial Chemotherapy (1990) 25:491-493.
5. Schwalbe RS, Stapelton JT, Gilligan HP: Emergence of vancomycin resistance in coagulase-negative staphylococci. New England Journal of Medicine (1987) 316:2432-2437.
6. Veach LA, Pfaller MA, Barrett M, Koontz FP, Wenzel RP: Vancomycin resistance in Staphylococcus haemolyticus causing colonization and bloodstream infection. Journal of Clinical Microbiology (1990) 28:2064-2068.
7. Herwaldt L, Boyken L, Pfaller M: In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis. European Journal of Clinical Microbiology & Infectious Diseases (1991) 10:1007-1012.
8. Biavasco F, Giovanetti E, Montanari MP, Lupidi R, Varaldo PE: Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species. Journal of Antimicrobial Chemotherapy (1991) 27:71-79.
9. Schwalbe RS, Ritz WJ, Verma PR, Barranco EA, Gilligan PH: Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus. Journal of Infectious Diseases (1990) 161:45-51.
10. Jett BD, Huycke MM, Gilmore MS: Virulence of enterococci. Clinical Microbiology Reviews (1994) 7:462-478.
11. Murray B: New aspects of antimicrobial resistance and the resulting therapeutic dilemmas. Journal of Infectious Diseases (1991) 163:1185-1194.
12. Van Horn KG, Gedris CA, Rodney KM: Selective isolation of vancomycin-resistant enterococci. Journal of Clinical Microbiology (1996) 34:924-927.
13. Roychoudhury S, Dotzlaf JE, Ghag S, Yeh WK: Purification, properties, and kinetics of enzymatic acylation with β-lactams of soluable penicillin-binding protein 2a. Journal of Biolological Chemistry (1994) 269:12067-12073.
14. De Lencastre H, De Lencastre A, Tomasz A: Methicillin-resistant Staphylococcus aureus isolates recovered from a New York City hospital: analysis by molecular fingerprinting techniques. Journal of Clinical Microbiology (1996) 34:2121-2124.
15. Reynolds PE: Structure, biochemistry and mechanism of action of glycopeptide antibiotics. European Journal of Clinical Microbiology & Infectious Diseases (1989) 8:943-950.
16. Walsh CT: Vancomycin resistance: decoding the molecular logic. Science (1993) 261:308-309.
17. Arthur M, Molinas C, Bugg TDH, Wright GD, Walsh CT: Evidence for in vivo incorporation of D-lactate into peptidoglycan precursors of vancomycin-resistant enterococci. Antimicrobial Agents and Chemotherapy (1992) 36:867-869.
18. Fraimow HS, Shlaes DM: Glycopeptide resistance in gram-positive pathogens. In: Jungkind DL, Mortenson JE, Fraimow HS, Calandra GB (eds): Antimicrobial resistance: a crisis in health care. Plenum Press, New York, (1995) pp 81-95.
19. Sieradzki K, Tomasz A: Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus. Journal of Bacteriology (1997) 179:2557-2566.
20. Sieradzki K, Tomasz A: A highly vancomycin-resistant laboratory mutant of Staphylococcus aureus. FEMS Microbiology Letters (1996) 142:2557-2366.
21. National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, M7-A4. NCCLS, Villanova, Pa., (1996).
22. Kacica M, Horgan MJ, Preston KE, Lepow M, Venezia RA: Relatedness of coagulase-negative staphylococci causing bacteremia in low-birthweight infants. Infection Control and Hospital Epidemiology (1994) 15:658-662.
23. Tomasz A, Nachman S, Leaf H: Stable classes of phenotypic expression on methicillin-resistant clinical isolates of staphylococci. Antimicrobial Agents and Chemotherapy (1991) 35:124-129.
24. Froggat JW, Johnston JL, Galetto DW, Archer GL: Antimicrobial resistance in nosocomial isolates of Staphylococcus haemolyticus. Antimicrobial Agents and Chemotherapy (1989) 33:460-466.
25. Jones R, Sader HS: The clinical impact of enterococcal resistance. Challenges in Infectious Disease (1993) 1:1-6.
26. Daum RS, Gupta S, Sabbagh R, Milewski WM: Characterization of Staphylococcus aureus isolates with decreased susceptibility to vancomycin and teicoplanin: isolation and purification of a constitutively produced protein associated with decreased susceptibility. Journal of Infectious Diseases (1992) 166:1066-1072.
27. Handwerger S, Pucci MJ, Volk KJ, Liu J, Lee MS: The cytoplasmic peptiodoglycan precursor of vancomycin-resistant Enterococcus faecalis terminates in lactate. Journal of Bacteriology (1992) 174:5982-5984.
28. Woodford N, Johnson AP, Morrison D, Speller DCE: Current perspectives on glycopeptide resistance. Clinical Microbiology Reviews (1995) 8: 585-615.
29. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. Journal of Antimicrobial Chemotherapy (1997) 40: 135-146.
30. Shlaes DM, Shlaes JH: Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin. Clinical Infectious Diseases (1995) 20:1071-1073.
31. Leclercq R, Bingen E, Su QH, Lambert-Zechovski N, Courvalin P, Duval J: Effects of combinations of β-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrobial Agents and Chemotherapy (1991) 35:92-98.
32. Sieradzki K, Villari P, Tomasz A: Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci. Antimicrobial Agents and Chemotherapy (1998) 42:100-107.